# Unveiling the Immune Related ceRNA Network in Osteoarthritis: Key Biomarkers and Therapeutic Targets

# Keywords

Osteoarthritis, Long non-coding RNA, Competitive endogenous RNA, Immune cell infiltration, Biomarkers, Therapeutic targets

# Abstract

# Introduction

The aim of this study was to explore the immune-related competitive endogenous RNA (ceRNA) network in osteoarthritis (OA), focusing on identifying differentially expressed long non-coding RNAs (lncRNAs), constructing a classification model, and uncovering the associations between these lncRNAs and immune cell subsets in OA.

#### Material and methods

Microarray data from the Gene Expression Omnibus (GEO) database was used to identify differentially expressed genes (DEGs) in synovial tissue of OA. A classification model was constructed using the Least Absolute Shrinkage and Selection Operator (LASSO) regression with selected IncRNAs. Computational methods like CIBERSORT were employed to quantify immune cell infiltration patterns, and weighted gene co-expression network analysis (WGCNA) was conducted to delineate co-expression modules. Finally, a ceRNA network was constructed to elucidate the regulatory interactions among IncRNAs, miRNAs, and mRNAs.

# Results

We identified 5927 DEGs, among which 47 were differentially expressed long non-coding RNAs (DELs). Seven DELs (DGCR11, FAM215A, HCG9, PART1, FAM106A, NOP14-AS1, PRORY) formed the basis of a classification model with an area under the receiver operating characteristic (ROC) curve of 1. We also examined the infiltration patterns of immune cells in OA tissues and found significant differences compared to healthy controls, indicating a strong immunological component in OA pathogenesis. WGCNA identified a turquoise module with a high correlation to OA traits.

# Conclusions

The study highlights the importance of ceRNA networks in understanding the complex pathogenesis of OA and offers a comprehensive framework for future research into potential diagnostic biomarkers and therapeutic targets.

#### Unveiling the Immune Related ceRNA Network in Osteoarthritis: Key Biomarkers and

# **Therapeutic Targets**

#### Abstract

**Introduction**: The aim of this study was to explore the immune-related competitive endogenous RNA (ceRNA) network in osteoarthritis (OA), focusing on identifying differentially expressed long non-coding RNAs (lncRNAs), constructing a classification model, and uncovering the associations between these lncRNAs and immune cell subsets in OA.

**Method**: Microarray data from the Gene Expression Omnibus (GEO) database was used to identify differentially expressed genes (DEGs) in synovial tissue of OA. A classification model was constructed using the Least Absolute Shrinkage and Selection Operator (LASSO) regression with selected lncRNAs. Computational methods like CIBERSORT were employed to quantify immune cell infiltration patterns, and weighted gene co-expression network analysis (WGCNA) was conducted to delineate co-expression modules. Finally, a ceRNA network was constructed to elucidate the regulatory interactions among lncRNAs, miRNAs, and mRNAs.

**Result**: We identified 5927 DEGs, among which 47 were differentially expressed long non-coding RNAs (DELs). Seven DELs (DGCR11, FAM215A, HCG9, PART1, FAM106A, NOP14-AS1, PRORY) formed the basis of a classification model with an area under the receiver operating characteristic (ROC) curve of 1. We also examined the infiltration patterns of immune cells in OA tissues and found significant differences compared to healthy controls, indicating a strong immunological component in OA pathogenesis. WGCNA identified a turquoise module with a high correlation to OA traits.

**Conclusion**: The study highlights the importance of ceRNA networks in understanding the complex pathogenesis of OA and offers a comprehensive framework for future research into potential diagnostic biomarkers and therapeutic targets.

Key words: Osteoarthritis, Long non-coding RNA, Competitive endogenous RNA, Immune cell infiltration, Biomarkers, Therapeutic targets

#### Introduction

Osteoarthritis (OA) is one of the most common joint diseases, profoundly impacting the quality of life for millions of individuals worldwide. It primarily arises from cartilage damage but eventually involves the entire joint [1, 2]. The incidence of OA increases significantly with age, making it a major public health concern in aging populations [3-5]. In 2021, it was estimated that more than 22% of adults over 40 years old suffered from knee OA, impacting over 500 million individuals worldwide and placing a substantial burden on healthcare systems [6].

Various risk factors, including age, gender, obesity, genetics, and joint injuries, have been associated with OA progression [7-9]. Pathologically, OA is characterized by joint cartilage degeneration and secondary osteophyte formation, accompanied by primary symptoms such as joint pain, swelling, and restricted mobility. These symptoms not only limit daily activities but also contribute to psychological distress, further exacerbating the overall burden of the disease [7, 10-12].

Recent advances in OA research have highlighted the critical roles of various molecular players, including cytokines, non-coding RNAs (ncRNAs), signaling pathways, and metalloproteinases [13-16].

Inflammatory cells and their associated mediators, including IL-6 and TNF- $\alpha$ , have been implicated in OA pathogenesis, inducing the expression of metalloproteinases (MMPs) and contributing to disease progression. Additionally, dysfunction of macrophages plays a pivotal role in OA pathogenesis. Despite advancements, OA remains incurable due to gaps in understanding the intricate pathogenic mechanisms underlying its onset and progression [17, 18]. Therefore, elucidating the pathological signaling pathways and key molecules involved in OA pathogenesis is imperative for identifying treatment targets and developing pharmaceutical interventions.

Long non-coding RNA (lncRNA), characterized by its sequence length exceeding 200 nucleotides, has emerged as a pivotal player in diverse biological processes, including epigenetic regulation, immune modulation, and signal transduction [19, 20]. In OA, several lncRNAs have been implicated in disease pathogenesis, showcasing their diverse roles in disease modulation [18, 21]. For instance, the m6A-mediated upregulation of AC008 has been found to promote OA progression through the miR-328-3p-AQP1/ANKH axis [22]. Conversely, exosomes derived from bone marrow mesenchymal stem cells, facilitated by the lncRNA LYRM4-AS1-GRPR-miR-6515-5p pathway, exhibit a protective influence on OA [23]. Additionally, DANCR and lncRNA KLF3-AS1 have been recognized as molecular sponges for miRNAs, regulating the expression of their target genes and impacting OA pathogenesis [24-26].

The concept of competitive endogenous RNA (ceRNA) has further expanded our understanding of the complex regulatory networks in OA. ceRNA networks involve interactions among lncRNAs, miRNAs, and mRNAs, which regulate gene expression and contribute to disease pathogenesis [27, 28]. Investigating these networks offers novel insights into the molecular underpinnings of OA, potentially identifying new therapeutic targets and diagnostic biomarkers. In this study, we aimed to explore the immune-related ceRNA network in OA through systematic analysis of transcriptome data from OA tissues and healthy controls. We identified differentially expressed lncRNAs and constructed a classification model incorporating key lncRNA features associated with OA. To further elucidate the functional relevance of these lncRNAs, we performed weighted gene co-expression network analysis (WGCNA) and built a ceRNA network to elucidate the regulatory interactions among lncRNAs, miRNAs, and mRNAs involved in OA pathogenesis. By integrating multi-omics data and bioinformatics analysis, our goal was to discover potential diagnostic biomarkers and therapeutic targets for OA, which could significantly impact the development of personalized medical approaches for individual patients. In summary, our study provided a comprehensive framework for understanding the immune-related ceRNA network in OA, offering new insights into the molecular mechanisms driving disease progression, and highlighting potential avenues for therapeutic interventions.

#### Methods

# Microarray data acquisition

Microarray data of synovial tissue in OA were obtained from GEO database. The training set included the GPL96 datasets (GSE55584, GSE55457, GSE55235) with 26 OA samples and 17 normal tissue samples. The testing set was comprised of the GPL96 dataset (GSE12021) with 8 OA samples and 10 normal tissue samples. For the training set, data integration, background correction, and normalization were performed using the "affy" package [29].

# **Classification Model Construction and Validation**

The Least Absolute Shrinkage and Selection Operator (LASSO) method was used as a regularization technique to construct a refined model by applying penalties. Based on the difference lncRNAs, we used

the 'glmnet' package to perform lasso regression and logistic regression analysis, followed by a 10-fold cross-validation model for building [30]. Principal Component Analysis (PCA) was performed by the 'pcaMethods' package in R [31]. Test sets were used to validate the above results.

### **Computational immune infiltration patterns**

CIBERSORT, a robust deconvolution method, was used to quantify the infiltration of immune cell populations [32]. We calculated the proportions of 22 immune cell subsets in the pooled samples. The comparison between normal tissue and OA group was tested by Wilcoxon test. The correlation between 24 lnRNAs and immune cell subsets was compared by Pearson correlation analysis. *P*-values < 0.05 were considered significant.

# Construction of weighted gene co-expression network and functional enrichment analysis

All mRNAs in the training set were used to construct a gene co expression network, which was implemented using the R software "WGCNA" package [33]. Subsequently, an appropriate soft threshold of 16 was selected, and the Dynamic Tree Cut method was used to generate modules, with minModuleSize set to 100 and height cutoff set to 0.2. For each module, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed using the 'clusterProfiler' package [34]. P < 0.05 was considered significant.

#### **Construction of ceRNA networks**

According to the ceRNA theory, the steps for constructing the lncRNA-miRNA-mRNA ceRNA network were as follows: (1) Differential miRNAs were screened from GSE143514, with the screening criteria set at |logFC| > 1 and P < 0.05; (2) Interactions between GUSBP11 and miRNAs were predicted using miRcode (http://www.mircode.org); (3) Interactions between miRNAs and miRNAs were predicted

using starbase (https://starbase.sysu.edu.cn/) and miRDB (http://mirdb.org/); (4) Intersection genes between the hub genes and the predicted mRNA in the pink module were selected, along with miRNAs interacting with GUSBP11, to construct a ceRNA network. Networks were visualized in Cytoscape software [35].

#### Result

#### Identification of differentially expressed lncRNAs and construction of a classification model

We selected the training set for analysis and identification of differently expressed gene (DEG). A total of 5927 DEGs were identified at *P*.adj < 0.05 (**Figure 1A**). Among them, 47 differently expressed lncRNAs (DELs) were identified in OA samples compared to lncRNAs in normal tissues, including 22 down-regulated genes and 25 up-regulated genes (**Figure 1B**).

To further narrow down the varieties and construct a classification model, we constructed LASSO regression models using 47 DELs. The final 7 lncRNAs (DGCR11, FAM215A, HCG9, PART1, FAM106A, NOP14-AS1, PRORY) formed the classification model (Figure 2A-B). The area under the receiver operating characteristic (ROC) curve for the training set was 1, which shows that the model combining 7 lncRNAs was more reliable than the classification of a single lncRNA (Figure 2C). A single lncRNA was used to predict the classification model with the highest AUC value of 0.95 (DGCR11) (Figure S1A). We verified model in the test set that the combined AUC was 0.944 (Figure 2D), while the highest single lncRNA was 0.889 (FAM106A) (Figure S1B). PCA analysis of the training and test sets showed that the normal samples had a completely different distribution pattern to the OA tissue (Figure 2E, 2F). These results suggested that the model can effectively discriminate between OA samples from healthy controls.

#### Associations between 7 selected lncRNAs and immune cell subsets

Next, we investigated the relationship between the 7 selected lncRNAs and immune cell infiltration in OA tissues. Using the CIBERSORT algorithm, we assessed the infiltration of 22 immune cell types in 26 OA tissue samples. The Wilcoxon rank test revealed that six immune cells showed significant differences in infiltrating levels between normal and OA tissues (**Figure 3A**). Compared with normal tissues, OA tissues had higher proportions of B cells memory, Macrophages M1, Macrophages M2, and Mast cells resting (all P < 0.05), while lower levels of B cells naive, Dendritic cells activated, Mast cells activated, T cells CD4 memory resting, and T cells CD8 (all P < 0.05).

To explore the relationship and immune signatures between seven selected lncRNAs, we performed Spearman's correlation analysis (**Figure 3B**). Heatmap showed that lncRNA PART1 had a positive correlation with B cells memory, Macrophages M1, Macrophages M2, and Mast cells resting (R > 0.3; P < 0.05). LncRNA NOP14-AS1 was positively correlated with B cells naive, Dendritic cells activated, Mast cells activated, T cells CD4 memory resting, and T cells CD8 (R > 0.3; P < 0.05). These results indicated the strong correlation between the 7 lncRNAs and immune cell infiltration in OA.

#### Construction of selected lncRNA-weighted gene co-expression networks

To delve deeper into the role of these lncRNAs, we constructed WGCNA using a soft threshold of 12, ensuring the network adhered to a scale-free distribution (**Figure 4A**). This approach resulted in the identification of 10 co-expression modules (**Figure 4B**), with the turquoise module showing the highest correlation with OA traits (**Figure 4C**). Within the turquoise module, DGCR11, FAM215A, HCG9, and PART1 showed significant positive correlations (R > 0.3, P < 0.05), while FAM106A, NOP14-AS1, and PRORY showed significant negative correlations (R < -0.3, P < 0.05) (**Figure 4D**).

Further analysis using GO and KEGG pathway enrichment was performed on the genes within the turquoise module (**Figure 5A**). To narrow the scope of the target genes of the selected lncRNAs, we performed a Module Membership-Gene Significance correlation analysis on the modules in the WGCNA network and selected the top 100 genes most related to the immune signature module and OA (**Figure 5B**). The VENN map showed that all hub genes overlapped with differentially expressed genes (**Figure 5C**). GO and KEGG analyses confirmed that these hub genes were primarily involved in immunity related pathways such as endolysosome, necroptotic process, glycosyltransferase activity, necroptosis, peroxisome, and Toll-like receptor signaling pathways (**Figure 5D**). These findings underscored the central role of the turquoise module and its associated lncRNAs in the immune response related to OA.

#### Construction of immune-related ceRNA network

Finally, we constructed an immune-related ceRNA network focusing on DGCR11, which showed the most significant positive correlation with the module (R = 0.79, P = 6e-11). Using the GSE143514 dataset, we identified miRNAs and mRNAs differentially expressed in OA, and their correlations with DGCR11 was explored. Specifically, hsa-miR-122-5p, hsa-miR-138-5p, and hsa-miR-1255a were upregulated, while hsa-miR-363-3p, hsa-miR-96-5p, hsa-miR-20b-5p, hsa-miR-106a-5p, hsa-miR-675-5p, hsa-miR-548f-5p, and hsa-miR-3944-5p were down-regulated (P.adj < 0.05). Spearman further analyzed the correlation between miRNAs and lncRNAs, in which hsa-miR-138-5p, hsa-miR-675-5p, hsa-miR-548f-5p, hsa-miR-3944-5p, and hsa-miR-1255a had a more significant correlation with lncRNA DGCR11 (|R|>0.3) (**Table 1**). In the ceRNA network, we identified these 5 miRNA nodes and 88 mRNA nodes associated with the lncRNA DGCR11 (**Figure 6A**). The Sankey diagram displayed the functional pathways corresponding to the hub genes in the network. RAB7A was associated with autophagy and mitophagy, SCP2 was associated

with fatty acid metabolism, and NPRL2 was associated with mTOR signaling pathway (**Figure 6B**). These results highlighted the pivotal role of DGCR11 in the ceRNA network and its potential impact on immune-related pathways in OA.

# Discussion

The ceRNA networks have opened new avenues for understanding the complex pathogenesis of OA. Our study has explored the immune-related ceRNA network in OA by leveraging a multi-omics approach. We identified a panel of DELs and constructed a classification model for OA with promising discriminatory power. Notably, the 7 lncRNAs included in the model exhibited significant correlations with immune cell infiltration patterns in OA tissues. Furthermore, we employed WGCNA to delineate co-expression modules and elucidate the functional relevance of lncRNAs within these modules. We identified a turquoise module with a strong correlation with OA traits and performed functional enrichment analysis on its associated hub genes, revealing enrichment in immune-related pathways. Finally, we constructed a ceRNA network centered around a key lncRNA DGCR11 within the turquoise module and identified potential miRNA and mRNA targets.

The associations between these seven lncRNAs and immune cell subsets further underscored the role of the immune system in OA pathogenesis. Our results indicated significant differences in the infiltration of various immune cells between normal and OA tissues, suggesting that immune responses play a crucial role in disease progression. The positive correlations between lncRNAs and immune cell subsets, such as B cells memory and macrophages, highlight the importance of immune modulation in OA. The ceRNA network constructed from lncRNA DGCR11 implicated various miRNAs and mRNAs, among which RAB7A and NPRL2 were found to be linked to autophagy and mTOR signaling, respectively.

The mTOR signaling pathway plays a pivotal role in cell growth, proliferation, and survival [36]. It has been implicated in various diseases, including cancer and metabolic disorders. In the context of OA, mTOR signaling is crucial because it regulates chondrocyte metabolism and cartilage homeostasis. Elevated mTOR activity has been observed in OA, leading to increased chondrocyte proliferation and reduced autophagic activity. These changes can contribute to the degeneration of cartilage and the formation of osteophytes, which are hallmark features of OA [37]. The association of NPRL2 with mTOR signaling in our study suggested that disruptions in this pathway could play a role in OA development and progression.

Autophagy is a cellular process that involves the degradation and recycling of cellular components, maintaining cell homeostasis and responding to cellular stress [38, 39]. It plays a protective role in chondrocytes by removing damaged organelles and misfolded proteins. In OA, decreased autophagy has been observed, leading to an accumulation of damaged cellular components and contributing to cartilage degradation [40]. RAB7A, identified in our ceRNA network, is associated with autophagy and mitophagy, which involves the selective removal of damaged mitochondria. STEAP3 interacts with Rab7A and RACK1, affecting the development and progression of osteoarthritis by regulating the MAPK and JAK/STAT signaling pathways [41]. The connection between RAB7A and autophagy in OA suggested that a lack of proper autophagic activity might contribute to disease progression. The reduced autophagic response in chondrocytes could lead to increased oxidative stress and cellular damage, ultimately affecting joint health.

The mTOR signaling pathway and autophagy are intricately linked, with mTOR acting as a negative

regulator of autophagy. Activation of mTOR suppresses autophagy by inhibiting the phosphorylation of autophagy-related proteins (ATGs), thereby blocking the autophagic process. Conversely, autophagy can modulate mTOR signaling by reducing the levels of mTOR activators, such as insulin growth factor (IGF-1) [36, 38, 39].

Understanding the relationship between mTOR signaling, autophagy, and OA can offer potential therapeutic targets. Modulating mTOR activity to restore balance in chondrocyte metabolism might slow disease progression, while promoting autophagy could reduce cellular damage and cartilage degradation [6, 18, 42, 43]. Future research in this area could focus on developing treatments that modulate mTOR activity and enhance autophagic responses in chondrocytes. This approach could help preserve joint function and alleviate OA symptoms, providing a targeted strategy to combat this debilitating disease.

Despite these promising findings, this study has several limitations that should be acknowledged. First, our study is primarily bioinformatics-based and lacks experimental validation. While the identified lncRNAs and their associations with immune cell subsets are promising, in vitro and in vivo experiments are necessary to confirm these findings and explore the underlying mechanisms. In addition, the constructed ceRNA network and the identified pathways, such as mTOR signaling and autophagy, offer potential therapeutic targets; however, their clinical relevance and efficacy in treating OA remain to be established through further research and clinical trials.

Overall, our study underscored the complexity of OA pathogenesis and emphasized the importance of ceRNA networks in understanding disease mechanisms. The integration of multi-omics data and bioinformatics approaches allowed us to uncover new insights into OA, highlighting key molecules and pathways that could serve as diagnostic biomarkers and therapeutic targets. This research contributes to the

growing body of knowledge surrounding OA and paves the way for developing personalized medical approaches tailored to individual patients. Nevertheless, further experimental validation and clinical trials are essential to translate these findings into effective treatment strategies for OA, and to fully realize the potential of the identified ceRNA networks in clinical practice.

# Conclusions

This study elucidates the role of immune-related ceRNA networks in osteoarthritis pathogenesis, providing a comprehensive framework for understanding the molecular mechanisms driving disease progression. We identified differentially expressed lncRNAs and constructed a classification model with high discriminatory power for OA, offering promising diagnostic and therapeutic insights. The significant correlations between lncRNAs and immune cell infiltration patterns suggested an immunological component in OA progression. The ceRNA network centered around DGCR11 revealed connections to autophagy and mTOR signaling pathways, which played a pivotal role in cartilage homeostasis. Understanding these molecular mechanisms opens new avenues for developing targeted therapies for OA. Future research should focus on experimental validation and clinical trials to translate these findings into effective treatment strategies that can alleviate OA symptoms and improve joint function.

#### References

1. Barnett R. Osteoarthritis. Lancet. 2018; 391(10134):1985.

2. Glyn-Jones S, Palmer AJ, Agricola R, et al. Osteoarthritis. Lancet. 2015; 386(9991):376-87.

3. Loeser RF, Collins JA, Diekman BO. Ageing and the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016; 12(7):412-20.

4. Sacitharan PK. Ageing and Osteoarthritis. Subcell Biochem. 2019; 91:123-59.

5. O'Brien MS, McDougall JJ. Age and frailty as risk factors for the development of osteoarthritis. Mech Ageing Dev. 2019; 180:21-8.

6. Quicke JG, Conaghan PG, Corp N, et al. Osteoarthritis year in review 2021: epidemiology & therapy. Osteoarthritis Cartilage. 2022; 30(2):196-206.

7. Felson DT, Lawrence RC, Dieppe PA, et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med. 2000; 133(8):635-46.

8. Vincent TL. Mechanoflammation in osteoarthritis pathogenesis. Semin Arthritis Rheum. 2019; 49(3S):S36-S8.

9. Abramoff B, Caldera FE. Osteoarthritis: Pathology, Diagnosis, and Treatment Options. Med Clin North Am. 2020; 104(2):293-311.

10. Katz JN, Arant KR, Loeser RF. Diagnosis and Treatment of Hip and Knee Osteoarthritis: A Review. JAMA. 2021; 325(6):568-78.

11. Fayet M, Hagen M. Pain characteristics and biomarkers in treatment approaches for osteoarthritis pain. Pain Manag. 2021; 11(1):59-73.

12. Young DA, Barter MJ, Soul J. Osteoarthritis year in review: genetics, genomics, epigenetics. Osteoarthritis Cartilage. 2022; 30(2):216-25.

13. Mehana EE, Khafaga AF, El-Blehi SS. The role of matrix metalloproteinases in osteoarthritis pathogenesis: An updated review. Life Sci. 2019; 234:116786.

14. Sondag GR, Haqqi TM. The Role of MicroRNAs and Their Targets in Osteoarthritis. Curr Rheumatol Rep. 2016; 18(8):56.

15. Rigoglou S, Papavassiliou AG. The NF-kappaB signalling pathway in osteoarthritis. Int J Biochem Cell Biol. 2013; 45(11):2580-4.

16. Boehme KA, Rolauffs B. Onset and Progression of Human Osteoarthritis-Can Growth Factors, Inflammatory Cytokines, or Differential miRNA Expression Concomitantly Induce Proliferation, ECM Degradation, and Inflammation in Articular Cartilage? Int J Mol Sci. 2018; 19(8).

17. Robinson WH, Lepus CM, Wang Q, et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016; 12(10):580-92.

18. Yao Q, Wu X, Tao C, et al. Osteoarthritis: pathogenic signaling pathways and therapeutic targets. Signal Transduct Target Ther. 2023; 8(1):1-31.

19. Herman AB, Tsitsipatis D, Gorospe M. Integrated lncRNA function upon genomic and epigenomic regulation. Mol Cell. 2022; 82(12):2252-66.

20. Kopp F, Mendell JT. Functional Classification and Experimental Dissection of Long Noncoding RNAs. Cell. 2018; 172(3):393-407.

21. Kong H, Sun ML, Zhang XA, et al. Crosstalk Among circRNA/lncRNA, miRNA, and mRNA in Osteoarthritis. Front Cell Dev Biol. 2021; 9:774370.

22. Yang J, Zhang M, Yang D, et al. m(6)A-mediated upregulation of AC008 promotes osteoarthritis progression through the miR-328-3p–AQP1/ANKH axis. Exp Mol Med. 2021; 53(11):1723-34.

23. Wang X, Li Z, Cui Y, et al. Exosomes Isolated From Bone Marrow Mesenchymal Stem Cells Exert a Protective Effect on Osteoarthritis via lncRNA LYRM4-AS1-GRPR-miR-6515-5p. Front Cell Dev Biol. 2021; 9:644380.

24. Wang Z, Chi X, Liu L, et al. Long noncoding RNA maternally expressed gene 3 knockdown alleviates lipopolysaccharide-induced inflammatory injury by up-regulation of miR-203 in ATDC5 cells. Biomed Pharmacother. 2018; 100:240-9.

25. Liu Y, Lin L, Zou R, et al. MSC-derived exosomes promote proliferation and inhibit apoptosis of chondrocytes via lncRNA-KLF3-AS1/miR-206/GIT1 axis in osteoarthritis. Cell Cycle. 2018; 17(21-

#### 22):2411-22.

26. Fan X, Yuan J, Xie J, et al. Long non-protein coding RNA DANCR functions as a competing endogenous RNA to regulate osteoarthritis progression via miR-577/SphK2 axis. Biochem Biophys Res Commun. 2018; 500(3):658-64.

27. Chen Y, Lin Y, Bai Y, et al. A Long Noncoding RNA (lncRNA)-Associated Competing Endogenous RNA (ceRNA) Network Identifies Eight lncRNA Biomarkers in Patients with Osteoarthritis of the Knee. Med Sci Monit. 2019; 25:2058-65.

28. Xiao K, Yang Y, Bian Y, et al. Identification of differentially expressed long noncoding RNAs in human knee osteoarthritis. J Cell Biochem. 2019; 120(3):4620-33.

29. Gautier L, Cope L, Bolstad BM, et al. affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004; 20(3):307-15.

30. Tay JK, Narasimhan B, Hastie T. Elastic Net Regularization Paths for All Generalized Linear Models. J Stat Softw. 2023; 106.

31. Stacklies W, Redestig H, Scholz M, et al. pcaMethods--a bioconductor package providing PCA methods for incomplete data. Bioinformatics. 2007; 23(9):1164-7.

32. Chen B, Khodadoust MS, Liu CL, et al. Profiling Tumor Infiltrating Immune Cells with CIBERSORT. Methods in molecular biology (Clifton, NJ). 2018; 1711:243-59.

33. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008; 9:559.

34. Wu T, Hu E, Xu S, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021; 2(3):100141.

35. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13(11):2498-504.

36. Liu GY, Sabatini DM. mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol. 2020; 21(4):183-203.

37. Sun K, Luo J, Guo J, et al. The PI3K/AKT/mTOR signaling pathway in osteoarthritis: a narrative review. Osteoarthritis Cartilage. 2020; 28(4):400-9.

38. Galluzzi L, Green DR. Autophagy-Independent Functions of the Autophagy Machinery. Cell. 2019; 177(7):1682-99.

39. Yamamoto H, Zhang S, Mizushima N. Autophagy genes in biology and disease. Nat Rev Genet. 2023; 24(6):382-400.

40. Tong L, Yu H, Huang X, et al. Current understanding of osteoarthritis pathogenesis and relevant new approaches. Bone Res. 2022; 10(1):60.

41. Sun C, Peng S, Lv Z, et al. Research of STEAP3 interaction with Rab7A and RACK1 to modulate the MAPK and JAK/STAT signaling in Osteoarthritis. Int Immunopharmacol. 2023; 124(Pt B):111034.

42. Latourte A, Kloppenburg M, Richette P. Emerging pharmaceutical therapies for osteoarthritis. Nat Rev Rheumatol. 2020; 16(12):673-88.

43. Cho Y, Jeong S, Kim H, et al. Disease-modifying therapeutic strategies in osteoarthritis: current status and future directions. Exp Mol Med. 2021; 53(11):1689-96.

#### **Figure legends**

**Figure 1.** Transcriptional expression profiles were disorder in control and osteoarthritis. (A) The volcano map showed the difference expressed genes between control and osteoarthritis. (B) The dendrogram showed the hierarchical clustering of control and osteoarthritis samples based on differently expressed lncRNAs (DELs), respectively.

**Figure 2.** LASSO regression models analysis of the differently expressed lncRNAs. (A) and (B) The LASSO results of lncRNA in train data. ROC curve of LASSO of 7 differential lncRNAs in (C) train set and (D) test set. PCA analyses of normal and OA samples in the (E) training and (F) test sets.

**Figure 3.** Association analysis between differential lncRNAs and immune infiltration. (A) The expression of immune cells in control and osteoarthritis tissues. (B) Correlation heatmap between differential LncRNA and immune cells.

**Figure 4.** The screening of osteoarthritis-related modules. (A) Soft thresholding (power=12) to construct network graphs conforming to scale-free distributions. (B) Dynamic tree cutting generates 10 co-expression modules. (C) The differential expression of eigengenes in osteoarthritis and controls. (D) Correlation heatmap between differential LncRNAs and osteoarthritis-related modules. FDR-corrected \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.

Figure 5. Screening of osteoarthritis-related module hubs. (A) GO and KEGG pathway enrichment in

turquoise module. (B) The screening criteria were top-100 high gene significance and high membership genes in turquoise module. (C) VENN diagram of differential genes and modular hub genes. (D) GO and KEGG pathway enrichment in top-100 high gene.

**Figure 6.** Establishment of a ceRNA network. (A) lncRNA-miRNA-mRNA network. Squares represent lncRNAs, triangles represent miRNAs, and circles represent mRNAs. (B) Significantly enriched mRNAs and biological processes in which they were involved.

Figure S1. ROC curve of LASSO of differential lncRNAs in (A) train set and (B) test set.

# Table

Table 1. Expression levels of 10 miRNAs between control and osteoarthritis group and correlation with

# lncRNA DGCR11.

	Log2FC	Adj.p	DGCR11.corr
hsa-miR-122-5p	6.55346363	0.02902733	-0.0238095
hsa-miR-138-5p	2.86315418	0.03738568	-0.3809524
hsa-miR-1255a	4.32322149	0.0479425	-0.3809524
hsa-miR-363-3p	-2.7264786	0.02902733	0.21428571
hsa-miR-96-5p	-3.1071837	0.02902733	0.02380952
hsa-miR-20b-5p	-3.3569607	0.02902733	-0.1428571
hsa-miR-106a-5p	-3.2888914	0.02902733	0.21428571
hsa-miR-675-5p	-3.4012809	0.02902733	0.5952381
hsa-miR-548f-5p	-3.042625	0.03738568	0.44312172
hsa-miR-3944-5p	-2.7537383	0.0479425	0.42171736



This study investigates osteoarthritis (OA) using microarray data from the GEO database. Seven <u>incRNAs</u> are identified for constructing a classification model. Computational immune infiltration analysis, gene co-expression networks, and <u>ceRNA</u> regulatory networks reveal immune-related pathways and potential biomarkers, with DGCR11 as a key <u>incRNA</u>.









В

						_	_	-
	B cells naive	0 14	0.06	0 33	-0.17	-0.10	-0.24	-0 14
	B cells memory	-0.18	-0.21	-0.39	0.34	0.20	0.23	0.28
hei	Plasma cells	0.07	0.07	-0.02	-0.21	-0.01	-0.04	0.13
	T.cells CD8	0.15	0.10	0.48	-0.25	-0.23	-0.18	0.16
	T.cells.CD4.memory.resting	0.25	0.22	0.52	-0.29	-0.27	-0.31	0.37
	T.cells.CD4.memory.activated	-0.25	-0.10	-0.39	0.18	0.07	0.11	80.0
	T.cells.follicular.helper	0.06	0.17	0.32	-0.30	-0.20	-0.11	0.26
	T.cells.regulatoryTregs.	0.23	0.12	0.19	-0.10	-0.01	-0.09	0.11
lov	T.cells.gamma.delta	-0.12	-0.12	-0.13	0.16	0.15	0.08	0.29
	NK.cells.resting	0.15	0.17	0.11	0.01	-0.10	-0.07	0.28
	NK.cells.activated	-0.07	-0.08	0.04	-0.05	-0.05	0.05	0.02
	Monocytes	0.04	0.04	0.19	-0.07	-0.11	-0.09	0.27
	Macrophages.M0	0.03	0.06	-0.34	0.11	0.05	0.12	0.33
	Macrophages.M1	-0.36	-0.58	-0.24	0.42	0.51	0.27	0.53
	Macrophages.M2	-0.24	-0.27	-0.28	0.39	0.20	0.21	0.24
	Dendritic.cells.resting	0.00	-0.00	0.16	-0.04	0.04	0.19	0.07
	Dendritic.cells.activated	0.42	0.57	0.50	-0.63	-0.55	-0.43	0.65
	Mast.cells.resting		-0.64		0.55	0.61	0.43	0.57
	Mast.cells.activated	0.60	0.61	0.81	-0.62	-0.63	-0.49	0.63
	Neutrophils	0.32	0.34	0.45	-0.41	-0.40	-0.40	0.55
		PRORY	FAM106A	NOP14-AS	PART1	DGCR11	FAM215A	HCG9



D



С yellow turquoise red purple pink magenta grey green brown blue black 0.0 R<sup>2</sup> 1.0 -1.0 -0.5 0.5

Module-IncRNAs relationships

MEpink	-0.57	-0.17	-0.22	-0.5	0.52	0.78	0.77
	(3e-05)	(0.3)	(0.1)	(4e-04)	(2e-04)	(2e-10)	(4e-10)
MEpurple	-0.7	-0.37	-0.55	-0.64	0.85	0.55	0.74
	(8e-08)	(0.01)	(7e-05)	(2e-06)	(9e-14)	(9e-05)	(4e-09)
MEgreen	0.12	-0.062	-0.096	0.077	-0.38	-0.065	-0.57
	(0.4)	(0.7)	(0.5)	(0.6)	(0.008)	(0.7)	(4e-05)
MEblack	-0.38	-0.36	-0.47	-0.3	0.21	0.49	0.11
	(0.01)	(0.01)	(0.001)	(0.04)	(0.2)	(5e-04)	(0.5)
MEbrown	-0.66	-0.48	-0.58	-0.6	0.47	0.9	0.47
	(6e-07)	(8e-04)	(2e-05)	(1e-05)	(9e-04)	(2e-17)	(9e-04)
MEyellow	-0.077	-0.14	-0.17	-0.093	0.14	0.48	0.085
	(0.6)	(0.4)	(0.3)	(0.5)	(0.4)	(8e-04)	(0.6)
MEblue	0.31 (0.03)	0.21 (0.2)	0.24 (0.1)	0.25 (0.1)	-0.52 (2e-04)	0.23 (0.1)	-0.45 (0.002)
MEred	0.66 (5e-07)	0.41 (0.005)	0.48 (8e-04)	0.55 (8e-05)	-0.59 (2e-05)	-0.19 (0.2)	-0.56 (4e-05)
Emagenta	0.51 (3e-04)	0.31 (0.04)	0.49 (6e-04)	0.41 (0.004)	-0.58 (3e-05)	-0.17 (0.3)	-0.44 (0.002)
Eturquoise	0.79	0.55	0.66	0.7	-0.94	-0.55	-0.9
	(6e-11)	(7e-05)	(7e-07)	(7e-08)	(9e-23)	(7e-05)	(1e-17)
MEgrey	0.046 (0.8)	0.14 (0.4)	0.21 (0.2)	0.017 (0.9)	-0.21 (0.2)	0.49 (6e-04)	0.029 (0.8)





